$787 Million is the total value of BVF INC/IL's 37 reported holdings in Q3 2017. The portfolio turnover from Q2 2017 to Q3 2017 was 42.9% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| BPMC | Sell | BLUEPRINT MEDICINES CORP | $70,182,000 | -13.0% | 1,007,354 | -36.7% | 8.92% | -28.8% |
| CCXI | Sell | CHEMOCENTRYX INC | $56,299,000 | -27.1% | 7,587,416 | -8.0% | 7.16% | -40.3% |
| ANAB | Sell | ANAPTYSBIO INC | $48,201,000 | +21.4% | 1,379,134 | -16.9% | 6.13% | -0.6% |
| LOXO | Sell | LOXO ONCOLOGY INC | $21,960,000 | -40.9% | 238,386 | -48.6% | 2.79% | -51.6% |
| CYTK | Sell | CYTOKINETICS INC | $17,995,000 | -25.3% | 1,241,021 | -37.6% | 2.29% | -38.9% |
| PIRS | Sell | PIERIS PHARMACEUTICALS INC | $17,203,000 | -2.6% | 2,986,562 | -14.5% | 2.19% | -20.3% |
| TOCA | Sell | TOCAGEN INC | $13,245,000 | -13.9% | 1,063,028 | -16.9% | 1.68% | -29.5% |
| ADRO | Sell | ADURO BIOTECH INC | $1,968,000 | -42.5% | 184,764 | -38.4% | 0.25% | -52.9% |
| FATE | Exit | FATE THERAPEUTICS INC | $0 | – | -391,386 | -100.0% | -0.20% | – |
| Exit | OREXIGEN THERAPEUTICS INCnote 2.750% | $0 | – | -10,000,000 | -100.0% | -0.78% | – | |
| NVLS | Exit | NIVALIS THERAPEUTICS INC | $0 | – | -2,644,806 | -100.0% | -0.99% | – |
| RXDX | Exit | IGNYTA INC | $0 | – | -700,000 | -100.0% | -1.12% | – |
| OMED | Exit | ONCOMED PHARMACEUTICALS INC | $0 | – | -4,400,289 | -100.0% | -2.28% | – |
| ACHN | Exit | ACHILLION PHARMACEUTICALS INC | $0 | – | -3,490,077 | -100.0% | -2.49% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| XENON PHARMACEUTICALS INC | 36 | Q3 2023 | 4.7% |
| PIERIS PHARMACEUTICALS INC | 30 | Q3 2023 | 2.8% |
| CYTOKINETICS INC | 29 | Q4 2020 | 11.8% |
| INFINITY PHARMACEUTICALS INC | 29 | Q2 2023 | 4.3% |
| XOMA CORP DEL | 28 | Q3 2023 | 7.3% |
| ARQULE INC | 27 | Q4 2019 | 4.8% |
| CHEMOCENTRYX INC | 26 | Q3 2019 | 13.8% |
| CYTOMX THERAPEUTICS INC | 26 | Q3 2023 | 5.3% |
| CORVUS PHARMACEUTICALS INC | 26 | Q3 2023 | 2.3% |
| ARRAY BIOPHARMA INC | 25 | Q2 2019 | 14.5% |
View BVF INC/IL's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 4 | 2024-05-13 |
| 13F-HR | 2024-02-14 |
| 4 | 2024-01-29 |
| 3 | 2024-01-26 |
| 4 | 2024-01-09 |
| 4 | 2023-12-20 |
| 4 | 2023-11-17 |
| 13F-HR | 2023-11-14 |
| 3 | 2023-11-13 |
View BVF INC/IL's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.